Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle, UK.
Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle, UK.
J Invest Dermatol. 2015 Jan;135(1):13-15. doi: 10.1038/jid.2014.362.
Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
奥马珠单抗，一种抗 IgE mAb，最近已被美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准用于治疗慢性特发性荨麻疹。Saini 等人（2014 年）（本期）报告了 ASTERIA I 试验，这是一项为期 40 周的随机、双盲、安慰剂对照的 III 期临床试验，评估奥马珠单抗治疗这种疾病的效果。
